Percutaneous biliary stent combined with brachytherapy using 125I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 35

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Cases. Dec 16, 2021; 9(35): 10979-10993
Published online Dec 16, 2021. doi: 10.12998/wjcc.v9.i35.10979

Full Size Figure Download Figure

Figure 6 Forest plot comparing mean difference in posttreatment reductions in serum indices.

Citation: Chen WY, Kong CL, Meng MM, Chen WQ, Zheng LY, Mao JT, Fang SJ, Chen L, Shu GF, Yang Y, Weng QY, Chen MJ, Xu M, Ji JS. Percutaneous biliary stent combined with brachytherapy using ¹²⁵I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis. World J Clin Cases 2021; 9(35): 10979-10993
URL: https://www.wjgnet.com/2307-8960/full/v9/i35/10979.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i35.10979

Chen WY, Kong CL, Meng MM, Chen WQ, Zheng LY, Mao JT, Fang SJ, Chen L, Shu GF, Yang Y, Weng QY, Chen MJ, Xu M, Ji JS. Percutaneous biliary stent combined with brachytherapy using ¹²⁵I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis. World J Clin Cases 2021; 9(35): 10979-10993 [PMID: 35047608 DOI: 10.12998/wjcc.v9.i35.10979]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.